Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

181. Peripheral dual-energy x-ray absorptiometry in the management of osteoporosis: the 2007 ISCD official positions.

Peripheral dual-energy x-ray absorptiometry in the management of osteoporosis: the 2007 ISCD official positions. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here

2010 International Society for Clinical Densitometry

182. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions.

Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded

2010 International Society for Clinical Densitometry

183. A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis

A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

184. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review

Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

185. Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment

Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment. Lansdale: HAYES, Inc.. 2010 Authors' conclusions Urinary cross-linked N-telopeptide of type collagen (NTx) is a biochemical marker of bone resorption. Urinary NTx can be measured noninvasively in the urine, and serum NTx can be quantified from blood. Urinary NTx has been recently proposed as an independent or complementary tool to bone mineral density (BMD) measures to identify bone loss, assess

2010 Health Technology Assessment (HTA) Database.

186. Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment

Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment. Lansdale: HAYES, Inc.. 2010 Authors' conclusions Urinary cross-linked N-telopeptide of type I collagen (NTx) is a biochemical marker of bone resorption. Urinary NTx can be measured noninvasively in the urine, and serum NTx can be quantified from blood. Urinary NTx has been recently proposed as an independent or complementary

2010 Health Technology Assessment (HTA) Database.

187. Osteodensitometry in primary and secondary osteoporosis

Osteodensitometry in primary and secondary osteoporosis Osteodensitometrie bei primärer und sekundärer osteoporose [Osteodensitometry in primary and secondary osteoporosis] Osteodensitometrie bei primärer und sekundärer osteoporose [Osteodensitometry in primary and secondary osteoporosis] IQWiG Citation IQWiG. Osteodensitometrie bei primärer und sekundärer osteoporose. [Osteodensitometry in primary and secondary osteoporosis] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG). IQWiG-Berichte 73. 2010 Authors' conclusions The key question of the present report was whether women or men with primary or secondary osteoporosis (but without pre-existing osteoporotic fractures) benefit from a health care strategy containing a diagnostic procedure (osteodensitometry) for determining low BMD and an increased fracture risk, as well as containing subsequent treatment, compared to a strategy without such an intervention. Due to the lack of studies with certainty

2010 Health Technology Assessment (HTA) Database.

188. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

189. A systematic review of healthcare professional-led education for patients with osteoporosis or those at high risk for the disease

A systematic review of healthcare professional-led education for patients with osteoporosis or those at high risk for the disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

190. Lasofoxifene in postmenopausal women with osteoporosis. Full Text available with Trip Pro

Lasofoxifene in postmenopausal women with osteoporosis. The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain.In this randomized trial, we assigned 8556 women who were between the ages of 59 and 80 years and had a bone mineral density T score of -2.5 or less at the femoral neck or spine to receive once-daily lasofoxifene (at a dose of either 0.25 mg or 0.5 mg) or placebo for 5 years. Primary end points were vertebral fractures, estrogen (...) women in the higher-dose lasofoxifene group. Rates of death per 1000 person-years were 5.1 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxifene group.In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. (ClinicalTrials.gov number

2010 NEJM Controlled trial quality: predicted high

191. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation

Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 77. 2010 Authors' objectives To determine the effectiveness and harms of osteoporosis screening in reducing fractures for men

2010 Health Technology Assessment (HTA) Database.

192. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Fardellone P, Cortet B, Legrand E, Bresse X, Bisot-Locard S, Vigneron AM, Beresniak A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of a single infusion of zoledronic acid against current treatment strategies for postmenopausal osteoporosis in France. The authors concluded that zoledronic acid

2010 NHS Economic Evaluation Database.

193. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of risedronate, compared with no intervention, for the prevention and treatment of osteoporosis in post-menopausal women, aged 50 years or older, who had various absolute risks of fracture, assessed using the World Health Organization's FRAX tool. From the perspective

2010 NHS Economic Evaluation Database.

194. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of strontium ranelate for osteoporosis treatment in post-menopausal women, with clinical risk factors, identified by the World Health Organization's fracture risk assessment tool; FRAX. Strontium ranelate was cost-effective for the treatment of established osteoporosis in women over the age of 65

2010 NHS Economic Evaluation Database.

195. Osteoporosis/fracture prevention clinical practice guidelines.

Osteoporosis/fracture prevention clinical practice guidelines. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Kaiser Permanente Care Management Institute

196. Increasing Options for the Treatment of Osteoporosis Full Text available with Trip Pro

Increasing Options for the Treatment of Osteoporosis 19671654 2009 08 27 2018 11 13 1533-4406 361 8 2009 Aug 20 The New England journal of medicine N. Engl. J. Med. Increasing options for the treatment of osteoporosis. 818-20 10.1056/NEJMe0905480 Khosla Sundeep S eng R01 AR027065 AR NIAMS NIH HHS United States Comment Editorial 2009 08 11 United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Antibodies, Monoclonal, Humanized 0 Bone Density Conservation Agents 0 Diphosphonates (...) 0 RANK Ligand 4EQZ6YO2HI Denosumab AIM IM N Engl J Med. 2009 Aug 20;361(8):756-65 19671655 N Engl J Med. 2009 Aug 20;361(8):745-55 19671656 Antibodies, Monoclonal adverse effects therapeutic use Antibodies, Monoclonal, Humanized Bone Density Conservation Agents adverse effects economics therapeutic use Denosumab Diphosphonates adverse effects economics therapeutic use Female Fractures, Bone prevention & control Humans Male Osteoporosis drug therapy RANK Ligand adverse effects therapeutic use

2009 NEJM

197. Teriparatide (rDNA origin) injection - Osteoporosis (glucocorticoid induced)

Teriparatide (rDNA origin) injection - Osteoporosis (glucocorticoid induced) Common Drug Review CEDAC Meeting – May 20, 2009; CEDAC Reconsideration – July 15, 2009 Page 1 of 3 Notice of CEDAC Final Recommendation – July 22, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION TERIPARATIDE (Forteo ™ – Eli Lilly Canada Inc.) New Indication: Glucocorticoid-Induced Osteoporosis Description: Teriparatide is a recombinant human parathyroid hormone (1-34 (...) ) that has the same physiological activity in bone and kidney as endogenous parathyroid hormone. The basis of the submission is a new Health Canada approved indication for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk for fracture. Teriparatide has been previously approved by Health Canada for the following: o The treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

198. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease.

Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 British Society of Gastroenterology

199. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials (Abstract)

Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials Vertebral fractures increase the risk of new vertebral fractures; however, we are not aware of any study addressing the risk of new vertebral fractures adjacent to existing vertebral fractures. Therefore, we sought to determine the influence of the number and severity of prevalent (preexisting) vertebral fractures on the risk (...) , compared with the placebo, raloxifene treatment reduced the risk of any new vertebral fracture, new adjacent vertebral fracture, and new nonadjacent vertebral fracture by 54%, 54%, and 53%, respectively.In untreated postmenopausal women with osteoporosis, nearly half of the incident vertebral fractures occur adjacent to an existing vertebral fracture. Both teriparatide and raloxifene can significantly reduce the occurrence of new adjacent and nonadjacent vertebral fractures.

2009 EvidenceUpdates Controlled trial quality: uncertain

200. Alendronate sodium / cholecalciferol - Osteoporosis

Alendronate sodium / cholecalciferol - Osteoporosis Common Drug Review CEDAC Meeting – May 20, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – June 17, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ALENDRONATE/CHOLECALCIFEROL (Fosavance ® 70/5600 – Merck Frosst Canada Ltd.) Indication: Osteoporosis Description: Fosavance 70/5600 is a fixed dose combination of alendronate, a bisphosphonate that inhibits bone resorption, and cholecalciferol (vitamin D 3 (...) ). Fosavance 70/5600 is approved by Health Canada for the treatment of osteoporosis in men and postmenopausal women. CEDAC previously reviewed Fosavance (referred to as Fosavance 70/2800 in this document), which contains alendronate 70 mg and 70 µg cholecalciferol, and recommended that it not be listed (see Fosavance Notice of CEDAC Final Recommendation on September 27, 2006). Dosage Forms: Supplied as tablets containing alendronate 70 mg and cholecalciferol 140 µg (5600 IU vitamin D 3 ). The recommended

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review